Article: Washington Roundup Drugmakers Failed to Keep Pledges for Phase IV Studies.(Report)

Byline: Donna Young, Washington Editor

WASHINGTON -- The FDA reported that as of Sept. 30, drug and biological manufacturers have failed to start more than 1,000 post-marketing safety and efficacy studies the firms committed to conduct as part of approval decisions for their products.

About 71 percent of post-approval, or Phase IV, commitment studies for pharmaceuticals and 33 percent for biologics have not been initiated, the FDA said in an April 24 Federal Register notice.

In addition, manufacturers of pharmaceutical products missed the deadline for submitting 37 percent of their annual reports about the status of Phase IV commitments, while ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!